Elevated serum C-reactive protein levels predict cardiovascular events in the Japanese coronary artery disease (JCAD) study

Circulation Journal

Volumn 73, Issue 1, 2009, Pages 78-85

  Shimada, Kenei ^a   Fujita, Masatoshi ^b   Tanaka, Atsushi ^c   Yoshida, Ken ^a   Jisso, Satoshi ^a   Tanaka, Hidemasa ^a   Yoshikawa, Junichi ^a   Kohro, Takahide ^d   Hayashi, Doubun ^d   Okada, Yoshihiro ^d   Yamazaki, Tsutomu ^d   Nagai, Ryozo ^d  

^a Osaka Ekisaikai Hospital   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

C reactive protein; Coronary artery disease; Japanese; Large observational cohort study

Indexed keywords

C REACTIVE PROTEIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRINKING BEHAVIOR; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART DEATH; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; JAPANESE; LEFT CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; OBESITY; PROTEIN BLOOD LEVEL; SMOKING HABIT; UNSTABLE ANGINA PECTORIS;

AGED; C-REACTIVE PROTEIN; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART ARREST; HEART FAILURE; HUMANS; JAPAN; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 58549092044     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0295     Document Type: Article

References (33)

1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
2. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2003; 42: 836-843.
3. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: Implications for future risk assessment: Results from a large cohort study in southern Germany. Circulation 2004; 109: 1349-1353.
4. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
5. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: The cardiovascular health study. Circulation 2005; 112: 25-31.
6. Biasucci LM. CDC, AHA, CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease. Application to Clinical and Public Health Practice: Clinical use of inflammatory markers in patients with cardiovascular diseases: A background paper. Circulation 2004; 110: e560-e567.
7. Sinning JM, Bickel C, Messow CM, Schnabel R, Lubos E, Rupprecht HJ, et al, AtheroGene Investigators. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: The AtheroGene study. Eur Heart J 2006; 27: 2962-2968.
8. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: Moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49: 2129-2138.
9. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, et al; PEACE Investigators. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115: 1528-1536.
10. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Robuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417-424.
11. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy [Thrombolysis in Myocardial Infarction]. J Am Coll Cardiol 1998; 31: 1460-1465.
12. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease: FRISC Study Group [Fragmin during Instability in Coronary Artery Disease]. N Engl J Med 2000; 343: 1139-1147.
13. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J 2000; 140: 324-328.
14. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: A comparative analysis: CAPTURE Investigators [Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial]. J Am Coll Cardiol 2003; 5: 1535-1542.
15. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
16. Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, et al, PROVE IT-TIMI 22 Investigators. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46: 1417-1424.
17. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006; 114: 281-288.
18. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Yui Y, et al. Fibrinolytic factors, serum lipid and C-reactive protein predicting cardiac events in Japanese patients with coronary atherosclerotic lesions. Jpn Circ J 1999; 63: 976-980.
19. Ichihara Y, Ohno J, Suzuki M, Anno T, Sugino M, Nagata K. Higher C-reactive protein concentration and white blood cell count in subjects with more coronary risk factors and/or lower physical fitness among apparently healthy Japanese. Circ J 2002; 66: 677-684.
20. Hase H, Tsunoda T, Tanaka Y, Takahashi Y, Imamura Y, Ishikawa H, et al. Risk factors for de novo acute cardiac events in patients initiating hemodialysis with no previous cardiac symptom. Kidney Int 2006; 70: 1142-1148.
21. Kinjo K, Sato H, Sakata Y, Nakatani D, Mizuno H, Shimizu M, et al. Relation of C-reactive protein and one-year survival after acute myocardial infarction with versus without statin therapy. Am J Cardiol 2005; 96: 617-621.
22. Hayashi D, Yamazaki T. Design and rationale of the Japanese Coronary Artery Disease (JCAD) Study: A large-scale, multicentered prospective cohort study. Jpn Heart J 2004; 45: 895-911.
23. Japanese Coronary Artery Disease (JCAD) Investigators. Current status of the background of patients with coronary artery disease in Japan. Circ J 2006; 70: 1256-1262.
24. Fujita M, Yamazaki T, Hayashi D, Kohro T, Okada Y, Nagai R; The JCAD Study Investigators. Comparison of cardiovascular events in patients with angiographically documented coronary narrowing with combined rennin-angiotensin system inhibitor plus statin versus rennin-angiotensin system inhibitor alone versus statin alone (from the Japanese coronary artery disease study). Am J Cardiol 2007; 100: 1750-1753.
25. Kohro T, Hayashi D, Okada Y, Yamazaki T, Nagai R; The JCAD Study Investigators. Effects of medication on cardiovascular events in the Japanese Coronary Artery Disease (JCAD) study. Circ J 2007; 71: 1835-1840.
26. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, et al. A reporting system on patients evaluated for coronary artery disease: Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51: 5-40.
27. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
28. Sano T, Tanaka A, Namba M, Nishibori Y, Nishida Y, Kawarabayashi T, et al. C-reactive protein and lesion morphology in patients with acute myocardial infarction. Circulation 2003; 108: 282-285.
29. Tanaka A, Shimada K, Sano T, Namba M, Sakamoto T, Nishida Y, et al. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J Am Coll Cardiol 2005; 45: 1594-1599.
30. Norja S, Nuutila N, Karhunen PJ, Goebeler S. C-reactive protein in vulnerable coronary plaques. J Clin Pathol 2007; 60: 545-548.
31. Pasceri V, Willerson JT, Yeh ET. Direct pro-inflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
32. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, et al. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094-2099.
33. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003; 108: 512-515.